Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization.

Sardar Pasha SPB, Sishtla K, Sulaiman RS, Park B, Shetty T, Shah F, Fishel ML, Wikel JH, Kelley MR, Corson TW.

J Pharmacol Exp Ther. 2018 Oct;367(1):108-118. doi: 10.1124/jpet.118.248088. Epub 2018 Aug 3.

PMID:
30076264
2.

Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.

Kelley MR, Wikel JH, Guo C, Pollok KE, Bailey BJ, Wireman R, Fishel ML, Vasko MR.

J Pharmacol Exp Ther. 2016 Nov;359(2):300-309. Epub 2016 Sep 8.

3.

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.

Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr.

Pharm Res. 2006 Jun;23(6):1133-43. Epub 2006 May 25.

PMID:
16715368
4.

Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents.

Lobb KL, Hipskind PA, Aikins JA, Alvarez E, Cheung YY, Considine EL, De Dios A, Durst GL, Ferritto R, Grossman CS, Giera DD, Hollister BA, Huang Z, Iversen PW, Law KL, Li T, Lin HS, Lopez B, Lopez JE, Cabrejas LM, McCann DJ, Molero V, Reilly JE, Richett ME, Shih C, Teicher B, Wikel JH, White WT, Mader MM.

J Med Chem. 2004 Oct 21;47(22):5367-80.

PMID:
15481975
5.

Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.

Bednarczyk D, Ekins S, Wikel JH, Wright SH.

Mol Pharmacol. 2003 Mar;63(3):489-98.

PMID:
12606755
6.

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):974-81.

PMID:
11961114
7.

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):964-73.

PMID:
11961113
8.

Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.

Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA.

J Pharmacol Exp Ther. 2002 May;301(2):427-34.

PMID:
11961040
9.

Three-dimensional quantitative structure-permeability relationship analysis for a series of inhibitors of rhinovirus replication.

Ekins S, Durst GL, Stratford RE, Thorner DA, Lewis R, Loncharich RJ, Wikel JH.

J Chem Inf Comput Sci. 2001 Nov-Dec;41(6):1578-86.

PMID:
11749585
10.

Progress in predicting human ADME parameters in silico.

Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH.

J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):251-72. Review.

PMID:
11274894
11.

Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.

Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.

Drug Metab Dispos. 2000 Aug;28(8):994-1002.

PMID:
10901712
12.

Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.

Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.

Pharmacogenetics. 1999 Aug;9(4):477-89.

PMID:
10780267
13.

1,2-Dibenzamidobenzene inhibitors of human factor Xa.

Herron DK, Goodson T Jr, Wiley MR, Weir LC, Kyle JA, Yee YK, Tebbe AL, Tinsley JM, Mendel D, Masters JJ, Franciskovich JB, Sawyer JS, Beight DW, Ratz AM, Milot G, Hall SE, Klimkowski VJ, Wikel JH, Eastwood BJ, Towner RD, Gifford-Moore DS, Craft TJ, Smith GF.

J Med Chem. 2000 Mar 9;43(5):859-72.

PMID:
10715153
14.

Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.

Ekins S, Bravi G, Wikel JH, Wrighton SA.

J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.

PMID:
10490933
15.

Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.

Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.

J Pharmacol Exp Ther. 1999 Jul;290(1):429-38.

PMID:
10381809
16.

Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 3. Enhancing activity by imposing conformational restriction in the C-4" side chain.

Bastian JA, Chirgadze N, Denney ML, Gifford-Moore DS, Sall DJ, Smith GF, Wikel JH.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):363-8.

PMID:
10091685
18.

Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 2. Exploring interactions at the proximal (S2) binding site.

Sall DJ, Briggs SL, Chirgadze NY, Clawson DK, Gifford-Moore DS, Klimkowski VJ, McCowan JR, Smith GF, Wikel JH.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2527-32.

PMID:
9873574
19.

Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.

Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, Vandenbranden M, Wrighton SA, Wikel JH.

J Pharmacol Exp Ther. 1999 Jan;288(1):21-9.

PMID:
9862748
20.

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.

Sall DJ, Arfsten AE, Bastian JA, Denney ML, Harms CS, McCowan JR, Morin JM Jr, Rose JW, Scarborough RM, Smyth MS, Um SL, Utterback BG, Vasileff RT, Wikel JH, Wyss VL, Jakubowski JA.

J Med Chem. 1997 Aug 29;40(18):2843-57.

PMID:
9288166
21.

Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.

Wikel JH, Bemis KG, Kurz K, Denney ML, Main BW, Moore RA, Smith T, Shingleton L, Holland DR.

Drug Des Discov. 1994 Jan;11(1):1-14.

PMID:
8068815
22.

3-Phenyl-4-hydroxyquinolin-2(1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex.

McQuaid LA, Smith EC, Lodge D, Pralong E, Wikel JH, Calligaro DO, O'Malley PJ.

J Med Chem. 1992 Sep 4;35(18):3423-5. No abstract available.

PMID:
1326635
23.

LY249933: a cardioselective 1,4-dihydropyridine with positive inotropic activity.

Holland DR, Wikel JH, Kauffman RF, Smallwood JK, Zimmerman KM, Utterback BG, Turk JA, Steinberg MI.

J Cardiovasc Pharmacol. 1989 Sep;14(3):483-91.

PMID:
2476630
24.

Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Fuller RW, Hahn RA, Snoddy HD, Wikel JH.

Biochem Pharmacol. 1984 Oct 1;33(19):2957-60.

PMID:
6333240
25.

Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.

Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND, Chamberlin JW.

J Med Chem. 1980 Apr;23(4):368-72.

PMID:
6247489

Supplemental Content

Loading ...
Support Center